This patent was mentioned in the Cerebrolysin thread, and may give some hints about the formulation and effects. Some of the MemoProve marketing literature mentions "patent pending," so I'm assuming this is the formulation for N-PEP-12, and MemoProve may contain other ingredients also.
The phrase "and the like" appearing at the end of every list of ingredients means that these are indicative, not comprehensive. Note the large number of vitamins, minerals, supplements (
esp. DMAE, huperazine, and caffeine) of which this may be comprised.
This is my transcription from the image, so watch for errors. I notice a couple in the patent while I was transcribing
Patent US2005227922: Neuroprotective dietary supplement
Publication Date: 2005-10-13
Applicant: EBWE PHARMA GES. M.H. NFG.KG
The novel dietary supplement mixture consists essentially of molecules having a molecular weight of less than 10 kDa and comprises at least one of the peptides defined by the following sequences:
Sequence 1: NMVPFPR
Sequence 2: ASAFQGIGSTHWVYDGVGNS
These peptides can be obtained by commonly known synthetic procedures. Sequence determination was performed by commonly known techniques such as mass spectrometry, tandem mass spectrometry, electrophoresis, chromatographic separation followed by sequencing and the like.
The novel dietary supplement mixture may further comprise additional peptides, having a molecular weight of less than 10 kDa.
It may further comprise amino acids.
Suitable amino acids are for example asparagine (N), methionine (M), glutamic acid (E), valine (V), proline (P), arginine ( R ), alanine (A), cysteine ( C ), phenylalanine (F), glutamine (Q), glycine (G), threonine (T), isoleucine (I), tryptophane (W), tyrosine (Y), threonine (T), serine (S), histidine (H), aspartic acid (D), lysine (K), leucine (L) and the like. The amino acids are preferably used in their opticall active form, most preferably L-amino acids are used.
The novel dietary supplement mixture may further comprise vitamins, such as vitamin A, different vitamins of the B group, vitamin C, vitamin D, E and/or K. Further it may comprise mineral substances and/or trace elements such as calcium, magnesium, iron, copper, sodium, zinc, manganese, iodine, potassium, selenium, chromium, molybdenium, fluorine, chlorine, phosphorous. Further ingredients may be caffeine and taurine, fatty acids such as Q-fatty aclids, alpha lipoic acid, phospholipids, phosphatidylserines, plant extracts, such as ginkgo biloba, huperzine, precursors of neurotransmitters like DMAE (Dimethylaminoethanol) and the like.
It may further comprise flavouring substances, colorants like titaniumdioxide ferric oxides and the like, and/or preserving agents and the like. Preserving agents may be Ethylparaben (P-Hydroxybenzoic acid ethyl ester), Benzalkonium Chloride, Benzethonium Chloride, Benzoic acid, Butylparaben (p-Hydroxybenzoic acid butyl ester), Methylparaben (p-Hydroxybenzoic acid methyl ester), Potassium sorbate, Propionic acid, Propylparaben (p-Hydroxybenzoic acid propyl ester), Sodium benzoate, Sodium propionate, Sorbic acid and the like.
The mixture further may comprise acceptable additives, fillers and/or excipients such as microcrystalline cellulose, maltodextrine, magnesium stearate, colloidal silica, silicon dioxide, lactose, maltose, carboxymethylcellulose sodium, cellulose modified, vegetable cellulose, calcium phosphate, sodium phosphate, vegetable glycerine, sodium starch, polyvinylpyrrolidone, polyvinylpolypyrrolidone, cellulose gum, stearic acid, gelatine, mannitol, sodium ascorbate, glycerine, receflour, maltodextrine dipotassium phosphate and the like.
Preferably the dietry supplement mixture of the invention comprises 10-30 wt% peptides, 2-20 wt% amino acids and up to 2-76 wt% additional ingredients, fillers and the like as defined above.
The dietary supplement mixture is applied orally in form of tablets, coated tablets, capsules, pastes, chewing tablets or drinking solutions. If a coated tablet is used the coating may be resistant against gastric juices, thus an enteric coated dosage form could be used. The dietary supplement mixture may in its oral dosage form be applied at least one time daily.
Examples 1-3 detail the tabletting procedure, example 4 a liquid preparation. Example 5 details an
in vitro experiment showing the neuroprotective effects on embryonic neuron cells. Example 6 was an experiment on the Morris Water Maze performance of rats given this preparation orally over 3 months; sample sizes were small but results were statistically significant.
Example 7 was a very small test on 6 health elderly subjects. Cognitive assessment was given on day 1, then again on day two, 6 hours after a single 180mg dose.
According to the results of this study, the mixture of the invention supports and improves memory performance in healthy elderly subjects after the administration of a single dose. The improvement induced by the mixture of the invention reached significant values in the word recognition task and in the total memory subscore of the ADAS, but not in the word recall item. The mixture of the invention also enhances, in a nonsignificant manner, performance in cognitive tasks of the SKT related to both, attention and memory performance. Individual SKT tasks where best effects after the treatment with the mixture of the invention were seen included the items arranging blocks, counting symbols and recognition memory. These effects indicate that the invention might potentiate attention and memory functions in adult-elderly people without cognitive impairment.
Contacting Ebewe regarding the oral bioavailability of the peptides themselves would still be interesting.
Edited by chrono, 25 November 2009 - 05:18 PM.
